Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 169

1.

Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.

Toussaint ND, Pedagogos E, Tan SJ, Badve SV, Hawley CM, Perkovic V, Elder GJ.

Nephrology (Carlton). 2012 Jul;17(5):433-44. doi: 10.1111/j.1440-1797.2012.01618.x. Review.

PMID:
22574672
[PubMed - indexed for MEDLINE]
2.

Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.

Molony DA, Stephens BW.

Adv Chronic Kidney Dis. 2011 Mar;18(2):120-31. doi: 10.1053/j.ackd.2011.02.004. Review.

PMID:
21406297
[PubMed - indexed for MEDLINE]
3.

[Clinical aspect of recent progress in phosphate metabolism. Phosphate retension, a powerful risk factor for mortality in chronic kidney disease (CKD)].

Imanishi Y.

Clin Calcium. 2009 Jun;19(6):828-35. doi: CliCa0906828835. Review. Japanese.

PMID:
19483278
[PubMed - indexed for MEDLINE]
4.

Phosphate: a stealthier killer than previously thought?

Gonzalez-Parra E, Tuñón J, Egido J, Ortiz A.

Cardiovasc Pathol. 2012 Sep-Oct;21(5):372-81. doi: 10.1016/j.carpath.2012.02.008. Epub 2012 Mar 16. Review.

PMID:
22425627
[PubMed - indexed for MEDLINE]
5.

Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?

Martin KJ, González EA.

Clin J Am Soc Nephrol. 2011 Feb;6(2):440-6. doi: 10.2215/CJN.05130610. Epub 2011 Feb 3. Review.

PMID:
21292848
[PubMed - indexed for MEDLINE]
Free Article
6.

Fibroblast growth factor 23 and the future of phosphorus management.

Wolf M.

Curr Opin Nephrol Hypertens. 2009 Nov;18(6):463-8. doi: 10.1097/MNH.0b013e328331a8c8. Review.

PMID:
19770756
[PubMed - indexed for MEDLINE]
7.

Ten-year experience with sevelamer and calcium salts as phosphate binders.

Raggi P, Vukicevic S, Moysés RM, Wesseling K, Spiegel DM.

Clin J Am Soc Nephrol. 2010 Jan;5 Suppl 1:S31-40. doi: 10.2215/CJN.05880809. Review.

PMID:
20089501
[PubMed - indexed for MEDLINE]
Free Article
8.

Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.

Hu P, Xuan Q, Hu B, Lu L, Wang J, Qin YH.

Int J Biol Sci. 2012;8(5):663-71. doi: 10.7150/ijbs.3886. Epub 2012 May 5. Review.

PMID:
22606047
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.

Damasiewicz MJ, Toussaint ND, Polkinghorne KR.

Nephrology (Carlton). 2011 Mar;16(3):261-8. doi: 10.1111/j.1440-1797.2011.01443.x. Review.

PMID:
21265930
[PubMed - indexed for MEDLINE]
10.

Therapeutic interventions for chronic kidney disease-mineral and bone disorders: focus on mortality.

Block GA.

Curr Opin Nephrol Hypertens. 2011 Jul;20(4):376-81. doi: 10.1097/MNH.0b013e328346f93f. Review.

PMID:
21519253
[PubMed - indexed for MEDLINE]
11.

Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community.

Larsson TE, Olauson H, Hagström E, Ingelsson E, Arnlöv J, Lind L, Sundström J.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):333-9. doi: 10.1161/ATVBAHA.109.196675. Epub 2009 Nov 30.

PMID:
19948843
[PubMed - indexed for MEDLINE]
Free Article
12.

Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease.

Isakova T.

Curr Opin Nephrol Hypertens. 2012 May;21(3):334-40. doi: 10.1097/MNH.0b013e328351a391. Review.

PMID:
22487610
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review.

Sigrist MK, Chiarelli G, Lim L, Levin A.

J Ren Care. 2009 Mar;35 Suppl 1:71-8. doi: 10.1111/j.1755-6686.2009.00064.x. Review.

PMID:
19222735
[PubMed - indexed for MEDLINE]
14.

Use of phosphate binders in chronic kidney disease.

Ketteler M, Biggar PH.

Curr Opin Nephrol Hypertens. 2013 Jul;22(4):413-20. doi: 10.1097/MNH.0b013e32836214d4. Review.

PMID:
23736841
[PubMed - indexed for MEDLINE]
15.

Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis.

Levin A.

Semin Dial. 2003 Mar-Apr;16(2):101-5. Review.

PMID:
12641872
[PubMed - indexed for MEDLINE]
16.

Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD).

Hruska KA, Choi ET, Memon I, Davis TK, Mathew S.

Pediatr Nephrol. 2010 Apr;25(4):769-78. doi: 10.1007/s00467-009-1337-0. Epub 2009 Nov 7. Review.

PMID:
19898875
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Fibroblast growth factor 23 and the heart.

Faul C.

Curr Opin Nephrol Hypertens. 2012 Jul;21(4):369-75. doi: 10.1097/MNH.0b013e32835422c4. Review.

PMID:
22531163
[PubMed - indexed for MEDLINE]
18.

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M.

Circulation. 2009 May 19;119(19):2545-52. doi: 10.1161/CIRCULATIONAHA.108.844506. Epub 2009 May 4.

PMID:
19414634
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Update on fibroblast growth factor 23 in chronic kidney disease.

Wolf M.

Kidney Int. 2012 Oct;82(7):737-47. doi: 10.1038/ki.2012.176. Epub 2012 May 23. Review.

PMID:
22622492
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.

Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE.

Atherosclerosis. 2009 Dec;207(2):546-51. doi: 10.1016/j.atherosclerosis.2009.05.013. Epub 2009 May 21.

PMID:
19524924
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk